Literature DB >> 32493739

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study.

Julie Toubiana1,2, Clément Poirault1, Alice Corsia3, Fanny Bajolle4, Jacques Fourgeaud5, François Angoulvant6, Agathe Debray1, Romain Basmaci7, Elodie Salvador3, Sandra Biscardi8, Pierre Frange9, Martin Chalumeau10,11, Jean-Laurent Casanova12,13, Jérémie F Cohen1,11, Slimane Allali1.   

Abstract

OBJECTIVES: To describe the characteristics of children and adolescents affected by an outbreak of Kawasaki-like multisystem inflammatory syndrome and to evaluate a potential temporal association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
DESIGN: Prospective observational study.
SETTING: General paediatric department of a university hospital in Paris, France. PARTICIPANTS: 21 children and adolescents (aged ≤18 years) with features of Kawasaki disease who were admitted to hospital between 27 April and 11 May 2020 and followed up until discharge by 15 May 2020. MAIN OUTCOME MEASURES: The primary outcomes were clinical and biological data, imaging and echocardiographic findings, treatment, and outcomes. Nasopharyngeal swabs were prospectively tested for SARS-CoV-2 using reverse transcription-polymerase chain reaction (RT-PCR) and blood samples were tested for IgG antibodies to the virus.
RESULTS: 21 children and adolescents (median age 7.9 (range 3.7-16.6) years) were admitted with features of Kawasaki disease over a 15 day period, with 12 (57%) of African ancestry. 12 (57%) presented with Kawasaki disease shock syndrome and 16 (76%) with myocarditis. 17 (81%) required intensive care support. All 21 patients had noticeable gastrointestinal symptoms during the early stage of illness and high levels of inflammatory markers. 19 (90%) had evidence of recent SARS-CoV-2 infection (positive RT-PCR result in 8/21, positive IgG antibody detection in 19/21). All 21 patients received intravenous immunoglobulin and 10 (48%) also received corticosteroids. The clinical outcome was favourable in all patients. Moderate coronary artery dilations were detected in 5 (24%) of the patients during hospital stay. By 15 May 2020, after 8 (5-17) days of hospital stay, all patients were discharged home.
CONCLUSIONS: The ongoing outbreak of Kawasaki-like multisystem inflammatory syndrome among children and adolescents in the Paris area might be related to SARS-CoV-2. In this study an unusually high proportion of the affected children and adolescents had gastrointestinal symptoms, Kawasaki disease shock syndrome, and were of African ancestry. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32493739     DOI: 10.1136/bmj.m2094

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  307 in total

1.  Cardiac markers of multisystem inflammatory syndrome in children (MIS-C) in COVID-19 patients: A meta-analysis.

Authors:  Yan Zhao; Jenil Patel; Ying Huang; Lijuan Yin; Lei Tang
Journal:  Am J Emerg Med       Date:  2021-05-18       Impact factor: 2.469

2.  Narcolepsy risk and COVID-19.

Authors:  Emmanuel Mignot; Steve Black
Journal:  J Clin Sleep Med       Date:  2020-10-15       Impact factor: 4.062

Review 3. 

Authors:  Paul Van Caeseele; Dana Bailey; Sarah E Forgie; Tanis C Dingle; Mel Krajden
Journal:  CMAJ       Date:  2020-12-07       Impact factor: 8.262

4.  The Trilogy of SARS-CoV-2 in Pediatrics (Part 2): Multisystem Inflammatory Syndrome in Children.

Authors:  Van L Tran; Sarah Parsons; Andrew Nuibe
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

5.  HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children.

Authors:  Rebecca A Porritt; Lisa Paschold; Magali Noval Rivas; Mary Hongying Cheng; Lael M Yonker; Harsha Chandnani; Merrick Lopez; Donjete Simnica; Christoph Schultheiß; Chintda Santiskulvong; Jennifer Van Eyk; John K McCormick; Alessio Fasano; Ivet Bahar; Mascha Binder; Moshe Arditi
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

6.  Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children.

Authors:  Pui Y Lee; Megan Day-Lewis; Lauren A Henderson; Kevin G Friedman; Jeffrey Lo; Jordan E Roberts; Mindy S Lo; Craig D Platt; Janet Chou; Kacie J Hoyt; Annette L Baker; Tina M Banzon; Margaret H Chang; Ezra Cohen; Sarah D de Ferranti; Audrey Dionne; Saddiq Habiballah; Olha Halyabar; Jonathan S Hausmann; Melissa M Hazen; Erin Janssen; Esra Meidan; Ryan W Nelson; Alan A Nguyen; Robert P Sundel; Fatma Dedeoglu; Peter A Nigrovic; Jane W Newburger; Mary Beth F Son
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

7.  Resuscitating Children with COVID-19: What the Pediatric Anesthesiologist Needs to Know.

Authors:  Richard J Ing; Debnath Chatterjee; Mark D Twite
Journal:  J Cardiothorac Vasc Anesth       Date:  2020-06-16       Impact factor: 2.628

8.  The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children.

Authors:  Rebecca A Porritt; Aleksandra Binek; Lisa Paschold; Magali Noval Rivas; Angela McArdle; Lael M Yonker; Galit Alter; Harsha K Chandnani; Merrick Lopez; Alessio Fasano; Jennifer E Van Eyk; Mascha Binder; Moshe Arditi
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

9.  Multisystem inflammatory syndrome (MIS-C) in Pakistani children: A description of the phenotypes and comparison with historical cohorts of children with Kawasaki disease and myocarditis.

Authors:  Shazia S Mohsin; Qalab Abbas; Devyani Chowdhary; Farah Khalid; Abdul Sattar Sheikh; Zuviya Ghazala Ali Khan; Nadeem Aslam; Omaima Anis Bhatti; Maha Inam; Ali Faisal Saleem; Adnan T Bhutta
Journal:  PLoS One       Date:  2021-06-21       Impact factor: 3.240

10.  Cutaneous Manifestations of COVID-19: A Systematic Review.

Authors:  Harjas Singh; Harleen Kaur; Kanhaiya Singh; Chandan K Sen
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-10-19       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.